相似文献
1
Practical considerations for the use of mTOR inhibitors.
Transplant Res. 2015 Dec 22;4(Suppl 1):5. doi: 10.1186/s13737-015-0029-5. eCollection 2015.
2
Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Pediatr Transplant. 2006 Sep;10(6):721-9. doi: 10.1111/j.1399-3046.2006.00577.x.
3
Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Transplant Proc. 2011 Mar;43(2):472-7. doi: 10.1016/j.transproceed.2011.01.054.
4
Immunosuppressive minimization with mTOR inhibitors and belatacept.
Transpl Int. 2015 Aug;28(8):921-7. doi: 10.1111/tri.12603. Epub 2015 Jun 8.
5
Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Clin Transplant. 2008 Jan-Feb;22(1):1-15. doi: 10.1111/j.1399-0012.2007.00739.x.
6
Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Transpl Immunol. 2014 Jun;31(1):22-32. doi: 10.1016/j.trim.2014.05.002. Epub 2014 May 24.
7
An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
Transpl Int. 2016 Mar;29(3):362-8. doi: 10.1111/tri.12732.
8
Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.
Ren Fail. 2011;33(8):789-94. doi: 10.3109/0886022X.2011.601826. Epub 2011 Jul 25.
9
Long-term maintenance therapy with calcineurin inhibitors: an update.
Transplant Proc. 2010 Nov;42(9 Suppl):S21-4. doi: 10.1016/j.transproceed.2010.09.015.
10
Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
Transpl Int. 2004 Jul;17(6):279-85. doi: 10.1007/s00147-004-0716-5. Epub 2004 Jun 22.
引用本文的文献
1
Frequency and Outcomes of Acute Kidney Injury in the First Month Post-transplant: A Study on Renal Transplant Recipients in a Resource-Limited Country.
Cureus. 2025 Mar 9;17(3):e80277. doi: 10.7759/cureus.80277. eCollection 2025 Mar.
2
The Evaluation and Management of Coronary Artery Disease in the Lung Transplant Patient.
J Clin Med. 2023 Dec 13;12(24):7644. doi: 10.3390/jcm12247644.
3
Calcineurin and mTOR inhibitors in kidney transplantation: integrative metamodeling on transplant survival and kidney function.
Int Urol Nephrol. 2024 Apr;56(4):1403-1414. doi: 10.1007/s11255-023-03754-3. Epub 2023 Sep 26.
4
High Dimensional Renal Profiling: Towards a Better Understanding or Renal Transplant Immune Suppression.
Curr Transplant Rep. 2019 Mar;6(1):60-68. doi: 10.1007/s40472-019-0225-1. Epub 2019 Jan 14.
5
Proceedings of the 13th international transplantation symposia: mTOR-inhibition: what have we learned and how so we best apply the learning.
Transplant Res. 2015 Dec 22;4(Suppl 1):4. doi: 10.1186/s13737-015-0027-7. eCollection 2015.
本文引用的文献
1
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
Am J Transplant. 2015 Jan;15(1):119-28. doi: 10.1111/ajt.12952. Epub 2014 Dec 17.
2
Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation.
Transplant Rev (Orlando). 2013 Oct;27(4):97-107. doi: 10.1016/j.trre.2013.06.001. Epub 2013 Aug 8.
3
Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation.
Am J Transplant. 2012 Oct;12(10):2744-53. doi: 10.1111/j.1600-6143.2012.04162.x. Epub 2012 Jul 19.
4
Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study.
Am J Transplant. 2012 Jul;12(7):1801-10. doi: 10.1111/j.1600-6143.2012.04036.x. Epub 2012 Apr 5.
5
Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.
Transpl Int. 2012 May;25(5):592-602. doi: 10.1111/j.1432-2277.2012.01465.x. Epub 2012 Mar 26.
6
Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.
Am J Transplant. 2012 May;12(5):1192-8. doi: 10.1111/j.1600-6143.2011.03961.x. Epub 2012 Feb 2.
7
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.
Am J Transplant. 2012 Feb;12(2):388-99. doi: 10.1111/j.1600-6143.2011.03840.x. Epub 2011 Nov 14.
8
The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients.
Am J Transplant. 2011 Aug;11(8):1633-44. doi: 10.1111/j.1600-6143.2011.03573.x. Epub 2011 Jun 10.
9
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Lancet. 2011 Mar 5;377(9768):837-47. doi: 10.1016/S0140-6736(10)62318-5. Epub 2011 Feb 19.
10
Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.
Kidney Int. 2011 Apr;79(8):897-907. doi: 10.1038/ki.2010.492. Epub 2010 Dec 29.
Zotero 插件